Formulations having an alpha v beta 3 antagonist and an alpha 2 beta 1 antagonist for anti-angionic therapy

Abstract

The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an αVβ1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

We claim: 
     
         1 . A pharmaceutical formulation comprising an αvβ3 antagonist, an α2β1 antagonist, and a pharmaceutically acceptable carrier. 
     
     
         2 . A pharmaceutical formulation comprising echistatin and VP12 (ECL12). 
     
     
         3 . An article of manufacture comprising an αvβ3 antagonist, an α2β1 antagonist, and instructions for administering an effective amount of the αvβ3 antagonist and an effective amount of the α2β1 antagonist to a subject. 
     
     
         4 . The formulation of  claim 1 , wherein the formulation functions to inhibit angiogenesis when contacted with a vascular cell tissue. 
     
     
         5 . The formulation of  claim 2 , wherein the formulation functions to inhibit angiogenesis when contacted with a vascular cell tissue. 
     
     
         6 . The formulation of  claim 1 , wherein the formulation functions to inhibit tumor invasion when contacted with a vascular cell tissue. 
     
     
         7 . The formulation of  claim 2 , wherein the formulation functions to inhibit tumor invasion when contacted with a vascular cell tissue. 
     
     
         8 . The formulation of  claim 1 , wherein the formulation functions to inhibit sprout angiogenesis when contacted with a vascular cell tissue. 
     
     
         9 . The formulation of  claim 2 , wherein the formulation functions to inhibit sprout angiogenesis when contacted with a vascular cell tissue. 
     
     
         10 . The formulation of  claim 1 , wherein the formulation functions to inhibit growth of solid tumors when contacted with a vascular cell tissue. 
     
     
         11 . The formulation of  claim 2 , wherein the formulation functions to inhibit growth of solid tumors when contacted with a vascular cell tissue. 
     
     
         12 . A system comprising the formulation of  claim 1  and an antiproliferative agent. 
     
     
         13 . A system comprising the formulation of  claim 2  and an antiproliferative agent. 
     
     
         14 . The article of manufacture of  claim 3 , further comprising an antiproliferative agent. 
     
     
         15 . A system comprising the formulation of  claim 1  and a source of radiation therapy. 
     
     
         16 . A system comprising the formulation of  claim 2  and a source of radiation therapy 
     
     
         17 . The formulation of  claim 4 , wherein the vascular tissue is a human endothelial tissue. 
     
     
         18 . The formulation of  claim 5 , wherein the vascular tissue is a human endothelial tissue. 
     
     
         19 . The formulation of  claim 2 , wherein the formulation functions to inhibit angiogenesis in a subject. 
     
     
         20 . The formulation of  claim 2 , wherein the formulation functions to inhibit the growth of a solid tumor in a subject.